An interventional study of Blood samples collection and Saliva samples collection in Bites Monkey, sponsored by Institut Pasteur. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Institut Pasteur · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Virus Diseases with a site in France — 9 open to participants now, 10 under way, 2 of them phase 3. Virus Diseases · France.
Among the 47 studies in Virus Diseases with a site in France, this one is the 15th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 45th registered.
656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.
Browse Virus Diseases studies →9 of the 47 studies in Virus Diseases with a site in France are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in France, United States, Canada and 3 more countries
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–100
Institut Pasteur · Sites in France
Ages 18+ · Women only · Healthy volunteers
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 65+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 8 · Phase 4 2
First in 1994; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 113 across the 26 interventional studies, 375 across the 21 observational. Of the 30 that completed or were terminated, 3 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 47 have an industry lead sponsor. The 10 most frequent:
Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.
Institut Pasteur has 3 studies filed under Virus Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Virus Diseases with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07097480Institut PasteurVirus Transmission to People Recently Bitten or With a History of Monkey Bites "SIMVIR | 2026-12 |
| NCT07030673Centre Hospitalier Universitaire, AmiensEarly Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection | 2027-03 |
| NCT07654283AusperBio Therapeutics Inc.Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | 2027-05-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 47 studies in Virus Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.
The objective of the study is to investigate the prevalence of STLV-1 and SFV infections following a nonhuman primate bite.
Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.
Compared to other individuals exposed to nonhuman primates (NHPs), travelers have two unique characteristics. First, they are typically exposed only once to simian infectious agents, in contrast to the repeated exposure experienced by other at-risk groups. If exposure results in an infection event, travelers may spread these infectious agents to geographic areas where they do not normally circulate.
To address the following main objective: to study the prevalence of STLV-1 and SFV infections following a nonhuman primate bite. The study plans to include subjects who have been recently bitten as well as those with a history of nonhuman primate bites. Blood and saliva samples will be collected from the subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Specific criteria for genetic analyses:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults recently bitten by a non-human primate and consulting at the Institut Pasteur medical center for prophylaxis as part of their care.
Procedure: Blood samples collection · Procedure: Saliva samples collection
Adults with a history of bites from a non-human primate who are consulting at the Institut Pasteur medical center as part of their routine care.
Procedure: Blood samples collection · Procedure: Saliva samples collection
Blood samples of 40 ml will be taken.
Saliva samples will be collected
Study the prevalence of STLV-1 and SFV infections following an NHP bite.
Detection of specific antibodies and viral DNA against both viruses in blood.
Time frame: 17 months
Identify risk and demographic factors associated with STLV-1 and SFV infection.
The study of associations between STLV-1 and SFV infection and demographic characteristics (age, sex) and those linked to the HNP bite (severity of injury, HNP species) will be analyzed by Fisher's exact test and the Mann-Withney test.
Time frame: 17 months
Determine the kinetics of appearance of viral markers (viral DNA and antibodies) for each virus
Measurement of viral markers (SFV RNA and DNA, STLV-1 DNA, virus-specific IgM and IgG) in blood and saliva.
Time frame: 17 months
Characterize detected STLV-1 and SFV viral strains
Determination of complete viral sequences and integration sites in the human genome.
Time frame: 17 months
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 61 interventional studies with no phase under Virus Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 16 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.